DFY.TO 0.66AGF.B.TO 0.05CDR.TO 0.33BLX -0.69KINS 0.34MCY -1.24DIS -2.04ATD.TO 0.6
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

50.32
-1.16 (2.25%)
as of Jul 17, 2026, 8:00:00 pm Market Open.
267 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 19, 2026, 12:00 am

This summary was created by AI, based on 32 opinions in the last 12 months.

Novo-Nordisk (NVO) faces significant challenges in the competitive pharmaceutical landscape, particularly within the GLP-1 weight-loss drug market, where it is losing ground to Eli Lilly (LLY). Several experts note that NVO's current valuation appears attractive, but concerns about its growth prospects persist due to competition, lack of product diversification, and market expectations. The company's management changes and ongoing pricing pressures have resulted in doubts about its ability to capitalize on the booming weight-loss and diabetes treatment markets. Analysts suggest a cautious approach, recommending that investors wait for clearer signs of recovery before committing to this stock. Despite its historical strengths, the overarching sentiment indicates that NVO might be viewed as a value trap in the short term.

consensus icon
Consensus
Negative
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
PAST TOP PICK

Novo-Nordisk(NVO)

Jul 21, 2020
(A Top Pick Aug 15/19, Up 38%) The biggest producer of insulin in the world. Type 2 diabetes is rapidly growing which helps NVO's growth. Very well-run. They have an obesity drug. A great demographic story. He continues to like it. He'd buy it here.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$68.77

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Novo-Nordisk(NVO)

Feb 07, 2020
International sales were up 11% and US at 1% due to pricing issues there. They are picking up market shares which gives them pricing power and allows them to go into India and China to earn higher margins. Getting out of the US is important for them. Once you get a moat around their product, the oral insulin pill and weight loss, it's smooth sailing. He's owned this since 1995. There are periods they struggle but over time, it's a gift that keeps giving. With the number of diabetics growing around the world, they will have good demand for its products. Right now, he would pause but he would have it in your portfolio.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$63.25

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Novo-Nordisk(NVO)

Jan 17, 2020
They have good exposure to the diabetes market, though less specialized growth in the next 10 years. They don't own it because their options are not liquid enough.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$61.31

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Jan 13, 2020
All pharma companies face pricing pressure in a US election year, because US candidates take shots at drug pricing. Also pharma companies need to keep putting new, successful drugs. NN succeeds in putting out new diabetes drugs (they lead this product segment globally).
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$58.97

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Novo-Nordisk(NVO)

Dec 02, 2019
He has avoided it because insulin and products to replace it have had a lot of price increases and he fears they will be looked at by politicians. It is a very defensive issue and should do better when the economy slows.
Photo of David FingoldDavid Fingold
No
Unlock Rating
$56.02

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Nov 29, 2019
FDA approval for a tablet diabetes drug. China and India will have a growing market for this as well. The trend will help the bottom line and profitability. He's owned it since 1997, and though it hasn't done much in the last 5 years, it is picking up. They are also completely off the grid and is very environmental. (Analysts’ price target is $62.73)
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$56.15

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Novo-Nordisk(NVO)

Nov 05, 2019

The pharma sector. Any picks? Pharma's problem is the US election cycle when candidates always bash big pharma. But these stocks are not expensive now, like JNJ which boasts 3 divisions (consumer, medical devices and pharma); and Novo Nordisk, which offers a diabetes pill and obesity pill. Buy a small position now as well as when they pull back during the election campaign, and certainly after the election. NVO increases its dividend perennially. The Dems and Republicans are equally critical of pharma.

Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$56.46

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Sep 26, 2019
Their business is in hemophilia and diabetes (450 million have it globally and the number will rise). They make an obesity drug (a pill, that's showing growth) and sell the most insulin in the world. (Analysts’ price target is $56.45)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$52.19

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Aug 15, 2019
Big franchise is in diabetes. Explosive, secular growth in diabetes, and NVO is the largest producer of insulin in the world. Plus biopharma business. Yield is 1.77%. (Analysts’ price target is $54.45)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$50.74

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 02, 2019
Over the next 25 years, type 2 diabetes will grow 55% led by India and China. Demand will be there. Novo needs to go and get this market. Starting to show better revenues and operating margins. They also have a new drug that is not just for diabetes but for weight loss.
Photo of David DriscollDavid DriscollUnlock Rating
$48.59

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Jun 21, 2019
About to come out with a pill instead of injections. Stock has popped recently. Type 2 diabetics are going to increase 50% in the next 2 years, mainly in India and China. Margins are being squeezed. Have to work harder to get sales. Likes what they're doing. Leaders in the industry.
Photo of David DriscollDavid DriscollUnlock Rating
$50.84

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Apr 24, 2019
The play is the growth in diabetes -- 11% per year. More drugs and medications will be required and this company has the best market share in the space. As this is a global issue, they worldwide coverage is a great advantage. Yield 3.2% (Analysts’ price target is $53.45)
Photo of Kash PashootanKash Pashootan
Owned
Unlock Rating
$48.37

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Novo-Nordisk(NVO)

Feb 15, 2019
The company understands that diabetes is growing in China and India. They've been raising market share there. International operations grew by 7%. Oral pills instead of insulin shots are coming out shortly. Increased dividend, a bit below average. Oral pills, if positive, could easily be a 1-5B blockbuster.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$49.76

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Dec 13, 2018
Given that markets will be lack luster he is looking for defensive names. They are focused on the diabetes space. The disease is growing at double digit rates. With their economies of scale, their profit margin is higher than their competitors. The most significant growth in diabetes is in emerging markets where they pay for the drugs themselves. They have to be able to reduce their prices in these markets. (Analysts’ price target is $49.60)
Photo of Kash PashootanKash Pashootan
Owned
Unlock Rating
$46.77

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Nov 08, 2018
Biggest growth is on diabetes. Market leader. The numbers were a little soft on the last report. Structural growth story. (Analysts’ price target is $45.85)
Photo of Darren SissonsDarren SissonsUnlock Rating
$44.67

Stock price when the opinion was issued

$50.32

As of Jul 17, 2026. Market Open.

biotechnologypharmaceutical
Showing 121 to 135 of 204 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX -5.4$68.95
RIO -0.52$90.15
MAR -4.9$366.24
META -18.53$646.01
AMT 1.14$170.06
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

DFY.TO 0.66$78.28
AGF.B.TO 0.05$22.89
CDR.TO 0.33$3.91
BLX -0.69$59.25
KINS 0.34$20.09

Popular Articles

Latest Sell Signals

NFLX -5.4$68.95
NFLX -5.4$68.95
CAT 3.11$880.28
NFLX -5.4$68.95
DOL.TO 1.92$190.87

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Bruce Campbell (2)

Stone Castle Investment Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like